Vandortuzumab vedotin explained

Vandortuzumab vedotin (INN; development code RG7450) is a humanized monoclonal antibody designed for the treatment of cancer.^{[1] [2]}

This drug was developed by Genentech/Roche. Development was discontinued in 2017.^[3]

Notes and References

1. http://www.ama-assn.org/resources/doc/usan/x-pub/vandortuzumab-vedotin.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Vandortuzumab Vedotin
2. World Health Organization . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112 . WHO Drug Information . 28 . 4 . 2014 . World Health Organization .
3. Web site: Vandortuzumab vedotin . AdisInsight . Springer Nature Switzerland AG .